MayoClinic.com taps Everyday Health for ads, minus pharma

Share this article:
Everyday Health added the Mayo Clinic's consumer website to its network of health properties, although pharmaceutical advertising on the site will continue to be handled by MayoClinic.com operators.

The deal, described as a “multi-year relationship," includes advertising duties for consumer packaged goods, OTC products, cosmetics, consumer retail and other business areas. Ben Wolin, CEO and co-founder of Waterfront Media (Everyday Health's parent company), said the exclusion of pharma advertising was based on MayoClinic.com's "longstanding relationships with several pharmaceutical companies," but that Everyday Health hopes to expand its relationship with the site over time.

Brian Nass, chair of Mayo Clinic's global products and services, corroborated Wolin's comments: "We already have many long-term, well established relationships with pharmaceutical advertisers and their agencies, and so did not see a reason to change those relationships."

MayoClinic.com hopes to "leverage [Everyday Health's] large sales structure to help us optimize advertising revenue across many categories," said Nass.

Everyday Health was attracted to MayoClinic.com based on "the quality of the brand, and the institution...we want to associate with great brands," said Wolin. "This is a signal to the marketplace about the kind of sites we work with."

MayoClinic.com garnered 4.5 million unique visitors in June, according to comScore data. Everyday Health's online network had 23.5 million unique visitors in May, by comScore's count, and stands to bring that number into the upper 20 millions after MayoClinic.com's numbers are added in.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.